School of Medicine
Showing 1-20 of 55 Results
-
Ranjana Advani
Saul A. Rosenberg, MD, Professor of Lymphoma
Current Research and Scholarly InterestsClinical investigation in Hodgkin's disease, non-Hodgkin's Lymphomas and cutaneous lymphomas. Experimental therapeutics with novel chemotherapy and biologically targeted therapies.
The research program is highly collaborative with radiation oncology, industry, pathology and dermatology. -
Rajni Agarwal
Professor of Pediatrics (Stem Cell Transplantation)
Current Research and Scholarly InterestsHematopoietic Stem cell biology-created a SCID mouse model to study engraftment of cord blood derived hematopoietic cells and use of this model to develop gene transfer technology for Fanconi anemia.
Clinical research interests are to develop new protocols to reduce Toxicity from the conditioning regimens for stem cell transplants, reducing graft vs host disease, treatment of viral infections post transplant and use of manipulated HSC graft in patients who receive haplo donor transplants. -
Michael Angelo
Associate Professor of Pathology
On Leave from 07/15/2025 To 02/11/2026BioMichael Angelo, MD PhD is a board-certified pathologist and assistant professor in the department of Pathology at Stanford University School of Medicine. Dr. Angelo is a leader in high dimensional imaging with expertise in tissue homeostasis, tumor immunology, and infectious disease. His lab has pioneered the construction and development of Multiplexed Ion Beam Imaging by time of flight (MIBI-TOF). MIBI-TOF uses secondary ion mass spectrometry and metal-tagged antibodies to achieve rapid, simultaneous imaging of dozens of proteins at subcellular resolution. In recognition of this achievement, Dr. Angelo received the NIH Director’s Early Independence award in 2014. His lab has since used this novel technology to discover previously unknown rule sets governing the spatial organization and cellular composition of immune, stromal, and tumor cells within the tumor microenvironment in triple negative breast cancer. These findings were found to be predictive of single cell expression of several immunotherapy drug targets and of 10-year overall survival. This effort has led to ongoing work aimed at elucidating structural mechanisms in the TME that promote recruitment of cancer associated fibroblasts, tumor associated macrophages, and extracellular matrix remodeling. Dr. Angelo is the recipient of the 2020 DOD Era of Hope Award and a principal investigator on multiple extramural awards from the National Cancer Institute, Breast Cancer Research Foundation, Parker Institute for Cancer Immunotherapy, the Bill and Melinda Gates Foundation, and the Human Biomolecular Atlas (HuBMAP) initiative.
-
Sally Arai
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsResearch interest in utilizing post-transplant adoptive cellular immunotherapy to reduce GVHD and relapse in patients with high risk hematologic malignancies.
-
Sean Bendall
Associate Professor of Pathology
On Partial Leave from 02/01/2026 To 10/31/2026Current Research and Scholarly InterestsOur goal is to understand the mechanisms regulating the development of human systems. Drawing on both pluripotent stem cell biology, hematopoiesis, and immunology, combined with novel high-content single-cell analysis (CyTOF – Mass Cytometry) and imagining (MIBI-Multiplexed Ion Beam Imaging) we are creating templates of ‘normal’ human cellular behavior to both discover novel regulatory events and cell populations as well as understand dysfunctional processes such as cancer.
-
Jonathan S. Berek, MD, MMSc
Laurie Kraus Lacob Professor
BioLaurie Kraus Lacob Professor
Stanford University School of Medicine
Founding Director, Stanford Women’s Cancer Center
Senior Advisor, Stanford Cancer Institute
Co-Chair, Senior Academy at Stanford Medicine
President, Stanford University Phi Beta Kappa
Director, MedArts Films
Faculty Director, Health Communication
Stanford Center for Health Education
A Stanford faculty member since 2005, Professor Berek is renowned for his many contributions to and expertise in gynecologic oncology, especially surgical innovation and techniques, and his research in immunology and immunotherapy. Through many laboratory and clinical investigations, he pioneered the use of regionally-administered immunotherapy in ovarian cancer patients. His early laboratory research focused on fundamental mechanisms of cancer immunology, elucidating growth regulatory pathways for cytokines and their receptors. His current research focuses on clinical trials of novel therapies and immunotherapies for ovarian cancer and collaborations on new diagnostics, screening techniques, and genetics.
An author and editor, Professor Berek has published more than 360 peer-reviewed manuscripts in the scientific literature, and numerous book chapters and monographs. His books, Berek & Hacker’s Gynecologic Oncology, now in its 7th edition, and Berek & Novak’s Gynecology, in its 17th edition, are leading texts in the field. He is the Series Editor for Operative Techniques in Gynecologic Surgery, for which five textbooks on various subspecialty topics in Obstetrics and Gynecology have been published. He serves as the Editor-in-Chief for Current Opinion in Obstetrics & Gynecology, and he is a former Editor-in-Chief of ASCO Connection, published by the American Society of Clinical Oncology.
Professor Berek received his Bachelor of Arts degree in English Literature and Theatre Arts, and a Master of Medical Sciences degree in biomedical sciences from Brown University. After earning his Doctor of Medicine from Johns Hopkins University School of Medicine, he completed an internship and residency at Harvard Medical School, Brigham & Women’s Hospital. Before moving to Stanford, he was on the faculty at the UCLA School of Medicine for more than two decades.
Professor Berek has received many honors and accolades. Dr. Berek is the 2019 Lifetime Achievement Honoree of the American Cancer Society for his many accomplishments in women’s cancer treatment and research. In 2022, he received a Lifetime Achievement Award from the International Society of Gynecologic Cancer for his contributions to the field of gynecologic oncology.
In addition to his medical career, Professor Berek is an active documentary filmmaker—creating and directing films on a variety of medical topics that are highlighted by patient stories. He is the Director and Producer of MedArts Films https://vimeo.com/medarts/videos. He directed a series of films for the Stanford Office of Medical Development, and many short films for the Stanford Center for Health Education that are found on YouTube at the Stanford Medicine Health Shelf. https://www.youtube.com/@Stanford_CHE/playlists
In collaboration with the Under One Umbrella Committee and Stanford Medical Center Development, Professor Berek has led a highly successful fundraising program for the Stanford Women’s Cancer Center. Since 2009, these Under One Umbrella philanthropy efforts have generated substantial support for innovative research programs in women’s cancer via concerts headlined by celebrities, including Nicole Kidman, Keith Urban, Trisha Yearwood, Garth Brooks, Tom Hanks, Rita Wilson, Carrie Underwood, Sheryl Crow, Vince Gill, Amy Grant, Darlene Love, and Harry Connick Jr.
https://www.facebook.com/StanfordWomensCancerCenter/ -
Alice Bertaina MD, PhD
Lorry I. Lokey Professor
Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.
-
Allison Betof, MD, PhD
Associate Professor of Medicine (Oncology)
BioDr. Allison Betof is an Associate Professor of Medicine (Oncology), Director of the Melanoma Program, Director of Solid Tumor Cellular Therapy, and Mark & Mary Stevens Endowed Scholar in Melanoma at Stanford University School of Medicine. Dr. Betof completed her MD and PhD at Duke University, Internal Medicine residency at Massachusetts General Hospital (Harvard University) and Medical Oncology Fellowship at Memorial Sloan Kettering Cancer Center. Dr. Betof’s laboratory focuses on understanding resistance to immune checkpoint blockade and cellular therapies for melanoma and other solid tumors. She is the Principal Investigator of clinical trials exploring novel treatments for immunotherapy-refractory melanoma and is internationally recognized for her expertise in brain/CNS metastasis and the use of novel cellular therapies. Dr. Betof has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy for the treatment of melanoma and other solid tumors. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), Melanoma Research Alliance, and Melanoma Research Foundation.
-
Ami Bhatt
Professor of Medicine (Hematology) and of Genetics
Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.
-
Scott D. Boyd, MD PhD
Stanford Professor of Food Allergy and Immunology and Professor of Pathology
Current Research and Scholarly InterestsOur goal is to understand the lymphocyte genotype-phenotype relationships in healthy human immunity and in immunological diseases. We apply new technologies and data analysis approaches to this challenge, particularly high-throughput DNA sequencing and single-cell monoclonal antibody generation, in parallel with other functional assays.
-
Eugene Butcher
Klaus Bensch Professor of Pathology
Current Research and Scholarly InterestsOur interests include:
-Lymphocyte migration and vascular specialization in immunity and inflammation;
-Single-cell and multi-omics dissection of vascular and immune system heterogeneity;
-AI-driven deorphanization of GPCRs and ligand discovery
-Reprogramming of vascular and immune niches in immunity and tolerance;
-Systems biology of immune cell targeting in health and disease -
Yueh-hsiu Chien
Professor of Microbiology & Immunology
Current Research and Scholarly InterestsContribution of T cells to immunocompetence and autoimmunity; how the immune system clears infection, avoids autoimmunity and how infection impacts on the development of immune responses.
-
Kyle Gabriel Daniels
Assistant Professor of Genetics and, by courtesy, of Neurosurgery (Adult Neurosurgery)
BioKyle obtained his BS in Biochemistry from the University of Maryland College Park in 2010, conducting undergraduate research with Dr. Dorothy Beckett, PhD. He obtained his PhD in Biochemistry with a certificate in Structural Biology and Biophysics. His dissertation is titled "Kinetics of Coupled Binding and Conformational Change in Proteins and RNA" and was completed in the laboratory of Dr. Terrence G. Oas, PhD. Kyle performed postdoctoral training with Dr. Wendell A. Lim, PhD at UCSF studying how CAR T cell phenotype is encoded by modular signaling motifs within chimeric antigen receptors.
Kyle's lab is interested in harnessing the principles of modularity to engineer receptors and gene circuits to control cell functions.
The lab will use synthetic biology, medium- and high-throughput screens, and machine learning to: (1) Engineer immune cells to achieve robust and durable responses against various cancer targets, (2) Coordinate behavior of multiple engineered cell types in cancer, autoimmune disease, and payload delivery, (3) Control survival, proliferation, and differentiation of hematopoietic stem cells (HSCs) and immune cells, and (4) Explore principles of modularity related to engineering receptors and gene circuits in mammalian cells. -
Kara Davis
Associate Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsChildhood cancers can be considered aberrations of normal tissue development. We are interested in understanding childhood cancers through the lens of normal development. Further, individual tumors are composed of heterogeneous cell populations, not all cells being equal in their ability to respond to treatment or to repopulate a tumor. Thus, we take single cell approach to determine populations of clinical relevance.
-
Mark M. Davis
Burt and Marion Avery Family Professor
Current Research and Scholarly InterestsMolecular mechanisms of lymphocyte recognition and differentiation; Systems immunology and human immunology; vaccination and infection.
-
Edgar Engleman
Professor of Pathology and of Medicine (Immunology and Rheumatology)
On Leave from 07/01/2025 To 06/30/2026Current Research and Scholarly InterestsDendritic cells, macrophages, NK cells and T cells; functional proteins and genes; immunotherapeutic approaches to cancer, autoimmune disease, neurodegenerative disease and metabolic disease.
-
C. Garrison Fathman
Professor of Medicine (Immunology and Rheumatology), Emeritus
Current Research and Scholarly InterestsMy lab of molecular and cellular immunology is interested in research in the general field of T cell activation and autoimmunity. We have identified and characterized a gene (GRAIL) that seems to control regulatory T cell (Treg) responsiveness by inhibiting the Treg IL-2 receptor desensitization. We have characterized a gene (Deaf1) that plays a major role in peripheral tolerance in T1D. Using PBC gene expression, we have provisionally identified a signature of risk and progression in T1D.
-
Andrew Fire
George D. Smith Professor of Molecular and Genetic Medicine and Professor of Pathology and of Genetics
Current Research and Scholarly InterestsWhile chromosomal inheritance provides cells with one means for keeping and transmitting genetic information, numerous other mechanisms have (and remain to be) discovered. We study novel cellular mechanisms that enforce genetic constancy and permit genetic change. Underlying our studies are questions of the diversity of inheritance mechanisms, how cells distinguish such mechanisms as "wanted" versus "unwanted", and of the consequences and applications of such mechanisms in health and disease.
-
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing.
